An appealing hypothesis, poorly demonstrated
There is an idea circulating in this sector with the standing of established fact, and it does not have that standing scientifically. It is used to justify substantial price differences between two categories of product.
The idea is simple: the compounds of a plant would act better together than separately. It is appealing, it is old, it is pharmacologically plausible, and it has never been demonstrated by a published comparative trial.
This page traces where the expression came from, what it asserts precisely, what the existing work does and does not establish, why the demonstration is difficult, and what remains verifiable once the argument is set aside.
⚠️ Scope. This page describes a process and what can be verified from documents. It does not describe what a product does to a person, gives no amounts, and does not replace a healthcare professional.
🔴 Where the expression came from
The founding paper
The term appears in a 1998 article by Raphael Mechoulam and Shimon Ben-Shabat. It described a phenomenon observed with endogenous compounds, not with plant extracts.
The shift in meaning
The expression was subsequently reused to denote the supposed interaction between the cannabinoids and terpenes of an extract. That is not what the paper described, and the shift happened without being flagged.
The popularisation
A review article by Ethan Russo, published in 2011, considerably widened the audience for the idea. It is a review, not a clinical trial, and it presents working hypotheses.
What happened next
The expression became a commercial argument. It now appears on thousands of sales pages, generally without reference and without qualification.
What the hypothesis asserts
The usual formulation
That the full set of compounds in an extract would produce a different, and superior, result to an isolated compound taken alone at the same quantity.
The compounds involved
Major and minor cannabinoids, terpenes, and sometimes flavonoids. The list varies between accounts, which is itself a sign of its imprecision.
The supposed mechanism
Interactions at shared receptors, in metabolism, or in bioavailability. Several different mechanisms are invoked depending on the author.
The standing of the assertion
A working hypothesis, formulated by serious researchers, calling for experiments nobody has yet conducted at scale.
The two versions of the idea
The weak version
That the composition of an extract bears on how it behaves. This version is reasonable and hard to dispute: two different mixtures are not identical.
The strong version
That a complete extract would be systematically superior to an isolate. This is the version that is sold, and it is the one lacking demonstration.
The difference between them
The first describes variability, the second asserts a hierarchy. Moving from one to the other requires comparative data that do not exist.
Why the confusion persists
Because the weak version is cited to lend credibility to the strong one. The slide is rhetorical and rarely made explicit.
What makes it plausible
The complexity of the mixture
An extract contains dozens of compounds at varying concentrations. That such a mixture behaves differently from a pure molecule is not remarkable.
Precedents in pharmacology
Interactions between substances are well established in other fields. The principle is therefore not exotic.
The in vitro observations
Several pieces of work on cells or isolated tissue describe differences between pure compound and extract. Those observations exist and are published.
What that is worth
A reason to regard the hypothesis as interesting and to test it. Not a reason to present it as settled.
🔴 What the work actually shows
Differences observed
On cellular models, several groups report gaps between extract and isolated molecule. Those gaps are real under the conditions of the experiment.
Contradictory results
Other work does not find those differences, or finds the reverse. The literature is not homogeneous, which is normal for an open question.
The absence of consensus
No synthesis concludes that a demonstration has been established. Recent reviews describe a hypothesis to be tested, not an acquired result.
What this means
That the state of knowledge is that of an open question. It is neither a refutation nor a confirmation.
The problem with in vitro studies
What they measure
The interaction between molecules and cells, in a controlled medium, at concentrations chosen by the experimenter.
What they do not measure
What happens in a whole organism, where absorption, distribution, metabolism and elimination all intervene. Those four stages change everything.
The concentration gap
Concentrations used in vitro frequently exceed attainable ones by several orders of magnitude. An observation at that scale does not transfer.
The general rule
A result on cells is a starting point for research, never an applicable conclusion. That holds here as in every other field.
The question of quantity
The amounts involved
In an extract, terpenes represent a few per cent at most, and minor cannabinoids fractions of a per cent. These are very small quantities.
The principal objection
For an interaction to produce a measurable outcome, sufficient quantities are generally required. The proportions present make this doubtful for several of the compounds invoked.
The response from proponents
That some interactions occur at low concentration, which does happen in pharmacology. The argument is admissible and requires demonstration case by case.
Where that leaves the question
Open, and dependent on the compound considered. A blanket assertion about an entire extract cannot be defended at that level of generality.
The absence of comparative trials
What would be required
A randomised double-blind trial comparing a full extract and an isolate, at equal quantity of the principal compound, against a predefined endpoint.
Why it does not exist
Cost, regulatory complexity, absence of economic incentive. Nobody has an interest in funding a study whose result could invalidate a sales argument.
What exists instead
Survey data, case series and testimonials. None of those formats supports a conclusion about a comparison.
The consequence
The most-used argument in the sector rests on the weakest category of evidence. That is a descriptive statement, not a judgement.
Why the demonstration is difficult
The variability of extracts
Two full extracts of the same variety do not have the same composition. Standardising the tested product is already a problem in itself.
The choice of endpoint
What exactly would be measured? Without an objective and agreed endpoint, the trial cannot be designed.
The size required
Detecting a modest difference demands a large sample. Costs rise quickly and the funding does not exist.
The regulatory setting
A clinical trial on a product without authorisation raises substantial administrative questions in most Member States.
What the European register says
The principle
No statement of benefit may accompany a product without an authorisation entered in the EU Register of nutrition and health claims.
The current position
That register contains no authorised entry for cannabidiol to this day. It contains none for a full extract or for the hypothesis discussed here either.
What follows
Presenting this hypothesis as an advantage of the product constitutes a claim. It is not authorised, whatever phrasing is used to work around it.
What remains sayable
That the extract contains such and such compounds at such and such contents, measured by an accredited laboratory. Composition description raises no problem.
How the argument is used
To justify a price
This is its principal use. A full extract sells for more than an isolate, and the hypothesis explains the gap.
To displace the comparison
It avoids the per-milligram comparison. If the product is presented as qualitatively different, the price calculation appears beside the point.
The cautious formulation
Informed sellers use the conditional and refer to articles. That changes nothing about the standing of the claim.
The signal that matters
The absence of any qualification. A page presenting the hypothesis as demonstrated fact has departed from what the literature supports.
Full spectrum, broad spectrum, isolate
The isolate
A single purified molecule, generally above ninety-nine per cent. Simple composition, verifiable, unambiguous.
Broad spectrum
An extract with the THC removed, retaining the other compounds. The exact composition should appear on the certificate, row by row.
Full spectrum
An extract retaining the full set of compounds, THC included, within regulatory limits. This is the category the argument mobilises.
What genuinely distinguishes them
A different composition, documented on a certificate. That is a fact. The value hierarchy between the three is an assertion.
What the certificate settles
The cannabinoid composition
Every row, major and minor, with contents. This is the best-documented part of any extract.
The terpene profile
Where commissioned. It shows what the extract actually contains rather than what the label suggests.
Compliance
Total THC, calculated as delta-9-THC plus THCA multiplied by 0.877. The only row with direct regulatory bearing.
The batch match
The number on the packaging must appear on the document. Without that, the certificate describes something else.
What it does not settle
Comparing two categories
A certificate describes composition, not use value. It does not permit saying that an extract is worth more than an isolate.
Validating the hypothesis
No row on an analytical report concerns an interaction. The document measures contents, and that is all.
Justifying a price gap
It supplies the inputs for the per-milligram calculation. What the calculation shows is then for the buyer to interpret.
Substituting for a trial
The question the hypothesis poses is clinical. No analytical document can answer it, by construction.
The calculation that still applies
The method
Price divided by the total milligrams of the principal compound. The result is euros per milligram and compares directly.
What it frequently reveals
That the gap between an isolate and a full extract far exceeds what the composition difference would justify on production cost grounds.
Its honest limitation
It compares two products on a single dimension. If the hypothesis were demonstrated, that dimension would not be the only relevant one.
Why do it anyway
Because in the absence of demonstration it is the only objective basis available. An imperfect calculation beats no criterion at all.
What the price gap covers
Real costs
A full extract requires a more delicate process than aggressive purification, and standardising it is harder. Part of the gap is explained.
A share of positioning
The remainder is commercial segmentation. That is legitimate in itself, but it is a pricing decision rather than a technical consequence.
What a buyer can do
Ask for both certificates, calculate, and decide whether the gap seems justified by what the documents show.
What they cannot do
Verify an assertion that is not demonstrated. On that specific point no documentary recourse exists.
How to put the question to a seller
The useful phrasing
Ask which publications the assertion rests on, and whether they are comparative trials or in vitro work. The answer is instructive.
What a good answer contains
A clear distinction between hypothesis and demonstration, and an acknowledgement that no comparative trial is published to date.
What a poor one contains
Statements of benefit, vague references to research, or an authorisation number that does not exist.
The tipping point
A seller who separates what they know from what they suppose deserves more trust than one who asserts. That holds well beyond this subject.
Common reasoning errors
The appeal to nature
That the plant contains these compounds together demonstrates nothing about their interaction. It is an argument from origin, not from evidence.
Confusing levels
A result on cells becomes, across three successive retellings, a statement about people. The slide is invisible and complete.
Reversing the burden
Asking for the hypothesis to be disproved. In science it is for the assertion to support itself, not for the doubt.
The argument from numbers
That many people believe it and many sites repeat it is not data. Repetition is not replication.
A short glossary
In vitro study
An experiment conducted on isolated cells or tissue, outside an organism. A research starting point, never an applicable conclusion.
Randomised double-blind trial
A protocol in which participants are allocated at random and neither they nor the assessors know which product was received. It is the reference for comparing two products.
Review article
A synthesis of existing literature, sometimes with hypotheses attached. It does not produce new data.
Full spectrum
An extract retaining the whole set of plant compounds, within the regulatory limits applying to total THC.
Claim
Any statement attributing a benefit to a product. It requires an authorisation entered in the European register to be used.
The five checks that apply to any product
The batch certificate
Request it with the number printed on the packaging. A general document for the product line does not cover this batch, and those differences are exactly what it should record.
Total THC
Delta-9-THC plus THCA multiplied by 0.877, because THCA becomes THC under heat and the limit applies to the sum, not to either value alone.
Price per milligram
A division, not an opinion. The only figure that makes two products comparable, whatever the format, process and pack size.
The claims
Without an authorisation number in the EU Register these are assertions, not data — and for cannabidiol that register contains no authorised entry to this day.
The seller’s details
Company name, address and contact. Without them there is also no counterparty to turn to if something turns out to be wrong.
How this connects to the rest
With terpenes
They are the compounds most often invoked. Their actual content, a few per cent at most, is one element of the debate about quantities.
With flavonoids
They are sometimes included in the argument although they are almost never measured. An assertion about undocumented compounds is doubly fragile.
With price per milligram
This is the calculation the argument allows people to avoid. Doing it systematically returns the comparison to a verifiable basis.
With reading a certificate
The document says what the product contains. The question of what that produces belongs to another kind of evidence, absent from the file.
What this is for in practice
To read a sales page
Notice whether the hypothesis is presented as such or as a fact. The difference indicates a seller’s seriousness better than most other signals.
To compare two products
Do the per-milligram calculation despite the argument. If the gap is considerable, it warrants at least a question.
To choose a category
Decide knowingly: the composition genuinely differs, the value hierarchy is not demonstrated. Both propositions are compatible.
To avoid disappointment
Buying a full extract expecting a guaranteed difference is buying a promise the document does not accompany.
Frequently asked questions
Where does the expression come from? From a 1998 paper by Mechoulam and Ben-Shabat, which described a phenomenon involving endogenous compounds rather than plant extracts.
Is the hypothesis demonstrated? No. No published randomised comparative trial establishes it to date. The existing work is essentially in vitro.
Is it refuted then? Not that either. It is an open question, pharmacologically plausible and not settled experimentally.
Why are there no trials? Cost, regulatory complexity and absence of economic incentive. No actor gains from funding a potentially unfavourable study.
What are cell studies worth? They orient research. The concentrations used and the absence of metabolism stop the results from transferring.
Can it be invoked commercially? No. That constitutes a claim, and the European register contains no authorised entry for cannabidiol.
Is a full extract different from an isolate? Its composition is, and the certificate shows it. It is the value hierarchy between the two that is not demonstrated.
How do I compare them? By price per milligram of the principal compound, using the batch certificates of both products.
What should I ask a seller? Which publications they rely on, and whether those are comparative trials. The quality of the answer is a reliable indicator.
Is the price gap justified? Part corresponds to real process costs. The rest is commercial positioning, which the calculation allows you to assess.
What we check and what we do not
We check what can be checked from documents: official registers, declared contents, certificates of analysis, arithmetic. We test no products, rank nothing, and assert no effects.
This is the subject where the gap between what is said and what is established reaches its maximum in this sector. The hypothesis is respectable, formulated by recognised researchers, and it deserves testing. What is problematic is not the idea but the standing given to it: that of a settled result, when it has never left the stage of a working hypothesis.
What stays solid fits in one sentence: the composition of an extract is verifiable on a certificate, its superiority is verifiable nowhere. The per-milligram calculation therefore continues to apply, for want of a documented reason to set it aside.